129 related articles for article (PubMed ID: 30661765)
1. The association between progesterone receptor expression and survival in women with adult granulosa cell tumors.
Puechl AM; Edwards J; Suri A; Nakayama J; Bean S; Gehrig P; Saks E; Duska L; Broadwater G; Ehrisman J; Horowitz N; Secord AA
Gynecol Oncol; 2019 Apr; 153(1):74-79. PubMed ID: 30661765
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of estrogen receptor and progesterone receptor status in young Chinese ovarian carcinoma patients.
Yang XY; Xi MR; Yang KX; Yu H
Gynecol Oncol; 2009 Apr; 113(1):99-104. PubMed ID: 19178934
[TBL] [Abstract][Full Text] [Related]
3. Estrogen receptor alpha and progesterone receptor expression in ovarian adult granulosa cell tumors and Sertoli-Leydig cell tumors.
Farinola MA; Gown AM; Judson K; Ronnett BM; Barry TS; Movahedi-Lankarani S; Vang R
Int J Gynecol Pathol; 2007 Oct; 26(4):375-82. PubMed ID: 17885486
[TBL] [Abstract][Full Text] [Related]
4. Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma.
Llaurado Fernandez M; Dawson A; Kim H; Lam N; Russell H; Bruce M; Bittner M; Hoenisch J; Scott SA; Talhouk A; Chiu D; Provencher D; Nourmoussavi M; DiMattia G; Lee CH; Gilks CB; Köbel M; Carey MS
Gynecol Oncol; 2020 Apr; 157(1):12-20. PubMed ID: 31954537
[TBL] [Abstract][Full Text] [Related]
5. Steroid hormone receptors and long term survival in invasive ovarian cancer.
Münstedt K; Steen J; Knauf AG; Buch T; von Georgi R; Franke FE
Cancer; 2000 Oct; 89(8):1783-91. PubMed ID: 11042574
[TBL] [Abstract][Full Text] [Related]
6. Tamoxifen-associated malignant endometrial tumors: pathologic features and expression of hormone receptors estrogen-alpha, estrogen-beta and progesterone; a case controlled study.
Wilder JL; Shajahan S; Khattar NH; Wilder DM; Yin J; Rushing RS; Beaven R; Kaetzel C; Ueland FR; van Nagell JR; Kryscio RJ; Lele SM
Gynecol Oncol; 2004 Feb; 92(2):553-8. PubMed ID: 14766247
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK
Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554
[TBL] [Abstract][Full Text] [Related]
8. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
[TBL] [Abstract][Full Text] [Related]
9. Expressions of estrogen and progesterone receptors in epithelial ovarian cancer: a clinicopathologic study.
Tangjitgamol S; Manusirivithaya S; Khunnarong J; Jesadapatarakul S; Tanwanich S
Int J Gynecol Cancer; 2009 May; 19(4):620-7. PubMed ID: 19509560
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical expression and prognostic significance of oestrogen receptor-alpha, oestrogen receptor-beta, and progesterone receptor in stage 1 adult-type granulosa cell tumour of the ovary.
Hutton SM; Webster LR; Nielsen S; Leung Y; Stewart CJ
Pathology; 2012 Dec; 44(7):611-6. PubMed ID: 23149378
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of hormonal receptor status of malignant ovarian tumors.
Tkalia IG; Vorobyova LI; Svintsitsky VS; Nespryadko SV; Goncharuk IV; Lukyanova NY; Chekhun VF
Exp Oncol; 2014 Jun; 36(2):125-33. PubMed ID: 24980769
[TBL] [Abstract][Full Text] [Related]
12. Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors.
Arias-Pulido H; Smith HO; Joste NE; Bocklage T; Qualls CR; Chavez A; Prossnitz ER; Verschraegen CF
Gynecol Oncol; 2009 Sep; 114(3):480-5. PubMed ID: 19560192
[TBL] [Abstract][Full Text] [Related]
13. Progesterone Receptor Expression Is an Independent Prognosticator in FIGO Stage I Uterine Leiomyosarcoma.
Davidson B; Kjæreng ML; Førsund M; Danielsen HE; Kristensen GB; Abeler VM
Am J Clin Pathol; 2016 Apr; 145(4):449-58. PubMed ID: 27149024
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical expression and prognostic value of ER, PR and HER2/neu in pancreatic and small intestinal neuroendocrine tumors.
Arnason T; Sapp HL; Barnes PJ; Drewniak M; Abdolell M; Rayson D
Neuroendocrinology; 2011; 93(4):249-58. PubMed ID: 21487213
[TBL] [Abstract][Full Text] [Related]
15. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
16. Adult granulosa cell tumours (GCT): clinicopathological outcomes including FOXL2 mutational status and expression.
Rosario R; Wilson M; Cheng WT; Payne K; Cohen PA; Fong P; Shelling AN
Gynecol Oncol; 2013 Nov; 131(2):325-9. PubMed ID: 24007948
[TBL] [Abstract][Full Text] [Related]
17. Steroid hormone receptor expression in ovarian cancer: progesterone receptor B as prognostic marker for patient survival.
Lenhard M; Tereza L; Heublein S; Ditsch N; Himsl I; Mayr D; Friese K; Jeschke U
BMC Cancer; 2012 Nov; 12():553. PubMed ID: 23176303
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical expression of estrogen and progesterone receptors and outcomes in patients with newly diagnosed uterine leiomyosarcoma.
Leitao MM; Hensley ML; Barakat RR; Aghajanian C; Gardner GJ; Jewell EL; O'Cearbhaill R; Soslow RA
Gynecol Oncol; 2012 Mar; 124(3):558-62. PubMed ID: 22085894
[TBL] [Abstract][Full Text] [Related]
19. Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients.
Liu S; Chia SK; Mehl E; Leung S; Rajput A; Cheang MC; Nielsen TO
Breast Cancer Res Treat; 2010 Jan; 119(1):53-61. PubMed ID: 19205877
[TBL] [Abstract][Full Text] [Related]
20. Survival outcome of weak estrogen/progesterone receptor expression in HER2 negative breast cancer is similar to triple negative breast cancer.
Liao GS; Dai MS; Hsu HM; Chu CH; Hong ZJ; Fu CY; Chou YC; Huang TC; Yu JC
Eur J Surg Oncol; 2017 Oct; 43(10):1855-1861. PubMed ID: 28756019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
